Enovis
Builds orthopedic implants, bracing, rehabilitation, and recovery products for care teams and patients.
Something off on this page? Send us feedback.
Profile
Sells orthopedic devices through Prevention & Recovery and Reconstructive segments, pairing braces, therapy equipment, and recovery technologies with joint implants, surgical instruments, and enabling tools. Sales are concentrated in the United States, with a meaningful international base in Europe and Asia-Pacific.
Operates as an orthopedic medical-technology company built from Colfax's DJO-centered medtech assets after the ESAB separation. Prevention & Recovery sells bracing, hot and cold therapy, bone-growth stimulation, compression, pain-management devices, and physical-therapy products. Reconstructive sells implants, instruments, and enabling technologies for shoulders, hips, knees, feet, ankles, and related procedures.
Most revenue comes from the United States, while international sales are anchored in Europe and Asia-Pacific. The portfolio connects orthopedic brands such as DonJoy, Aircast, Chattanooga, Enovis Surgical, LimaCorporate, ARVIS, STAR Ankle, and DynaNail.
Execution depends on product quality, surgeon and clinician relationships, reimbursement, healthcare regulation, and integrating acquired businesses such as Lima. Competition is fragmented in prevention and recovery and includes much larger reconstructive implant companies.
Company facts
Categories
Key statistics
Year to date −6.1% · Average volume (30d) 1.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Reiterate | Buy | $50 | $45 |
| Aug 7, 2026 | BMO Capital | Reiterate | Outperform | $29 | $30 |
| Jul 28, 2026 | UBS | Target | $50 | $51 | |
| Jul 8, 2026 | BMO Capital | Initiate | Outperform | $29 | |
| Jul 6, 2026 | Evercore ISI | Target | $36 | $32 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $0.85 | $0.90 | +6.3% | $581.8M | $582.8M | +0.2% | −12.82% |
| May 7, 2026Q1 FY26 | $0.82 | $0.89 | +8.5% | $572.0M | $589.2M | +3.0% | −2.68% |
| Feb 26, 2026Q4 FY25 | $0.81 | $0.95 | +17.3% | $582.9M | $575.8M | −1.2% | +0.20% |
| Nov 6, 2025Q3 FY25 | $0.67 | $0.75 | +11.9% | $584.3M | $548.9M | −6.1% | −1.27% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $558.8M | $564.5M | $548.9M | $575.8M | $589.2M | $582.8M | |
| Gross profit | $332.2M | $334.7M | $286.7M | $349.4M | $323.6M | $359.2M | |
| Operating income | −$42.9M | −$16.1M | $9.0M | $48.3M | $20.3M | $17.4M | |
| Net income | −$56.0M | −$36.7M | −$571.1M | −$520.6M | −$8.8M | −$1.2M | |
| Diluted EPS | −$0.99 | −$0.64 | −$10.06 | −$9.17 | −$0.15 | −$0.02 | |
| Gross margin | 59.5% | 59.3% | 52.2% | 60.7% | 54.9% | 61.6% | |
| Operating margin | -7.7% | -2.8% | 1.6% | 8.4% | 3.4% | 3.0% |
Fiscal years (4-quarter sums)FY21 $2.62B · FY22 $1.56B · FY23 $1.71B · FY24 $2.11B · FY25 $2.25B
Revenue by geography · FY24
Balance sheet, Jul 3, 2026Cash & short-term investments $12.6M · Total debt $1.37B · Total assets $3.77B · Shareholders' equity $1.48B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 57.56M · Float 56.59M · 98.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.30M | 17.89% | 13F | Aug 7, 2026 |
| American Century Companies Inc | 6.11M | 10.61% | 13F | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 3.93M | 6.82% | 13F | Aug 13, 2026 |
| Rubric Capital Management LP | 3.90M | 6.78% | 13G | Aug 14, 2026 |
| Diamond Hill Capital Management Inc | 2.79M | 5.00% | 13G | Feb 6, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 15, 2026 | Oliver Engert | officer: Chief Administrative Officer | +1,000 | $20.92 |
| Jun 11, 2026 | Oliver Engert | officer: Chief Administrative Officer | +1,200 | $21.62 |
| Jun 10, 2026 | Oliver Engert | officer: Chief Administrative Officer | +1,000 | $23.00 |
| Jun 1, 2026 | Oliver Engert | officer: Chief Administrative Officer | +1,000 | $22.22 |
| Mar 13, 2026 | Oliver Engert | officer: Chief Administrative Officer | +1,000 | $23.74 |
Peers
- Stryker
Largest reconstructive overlap in joints, extremities, and robotics
- Zimmer Biomet
Focused joint-reconstruction peer with ROSA robotics
- Johnson & Johnson
DePuy Synthes overlap across joints, trauma, and VELYS robotics
- Smith & Nephew (ADR)
Additional reconstructive peer in joints and CORI robotics
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Enovis | $24.90 | +0.08% | $1.43B | — | 6.6 | 0.6 | +3.2% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Median | 27.8 | 20.6 | 3.6 | +5.7% |